New diabetes clinical trial: Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

Published on: September 28, 2023 at 11:00AM
Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: HSK7653 10 mg;   Drug: HSK7653 25 mg;   Drug: HSK7653 50 mg;   Drug: Placebo
Sponsor:   Haisco Pharmaceutical Group Co., Ltd.
Completed
https://ift.tt/3xMX0db